Autres langues Natera, Inc.

Actions

NTRA

US6323071042

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/05/2024			Varia. 5j.	Varia. 1 janv.
94,15 ^USD	+1,37%		+2,90%	+50,30%

01/05	Natera, Inc. lance un test de détection du RhD fœtal pour aider les gynécologues-obstétriciens et leurs patients à faire face à la pénurie d'IgR.	CI
18/04	Un initié de Natera a vendu des actions d'une valeur de 7 265 651 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Natera to Report its First Quarter 2024 Results on May 9	01/05
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage	01/05
Natera, Inc. Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage	01/05
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications	22/04
Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing	18/04
Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing	18/04
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation	11/04
Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation	11/04
Natera Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heart dd-cfDNA Test for Heart Transplant Recipients	09/04
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients	08/04
Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients	08/04
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer	08/04
North American Morning Briefing : Inflation Data, -2-	08/04
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise	05/04
Natera Insider Sold Shares Worth $2,468,822, According to a Recent SEC Filing	05/04
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer	05/04
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103, A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer	02/04
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer	01/04
Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer	01/04
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer	18/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Natera, Inc.

Actions

NTRA

US6323071042

Autres langues

Filtres